The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
Open Access
- 17 December 2021
- journal article
- editorial
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (5) , 493-495
Abstract
Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.Keywords
This publication has 8 references indexed in Scilit:
- Polygenic risk scoring of human embryos: a qualitative study of media coverageBMC Medical Ethics, 2021
- Problems with Using Polygenic Scores to Select EmbryosNew England Journal of Medicine, 2021
- Improving reporting standards for polygenic scores in risk prediction studiesNature, 2021
- Polygenic risk scores: from research tools to clinical instrumentsGenome Medicine, 2020
- Direct-to-consumer genetic testingBMJ, 2019
- The illusion of polygenic disease risk predictionGenetics in Medicine, 2019
- Polygenic Risk Scores That Predict Common Diseases Using Millions of Single Nucleotide Polymorphisms: Is More, Better?Clinical Chemistry, 2019
- Evaluation of polygenic risk models using multiple performance measures: a critical assessment of discordant resultsGenetics in Medicine, 2019